mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-05-14
DOI
10.1038/s41598-018-26298-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA
- (2018) Kirtika H. Asrani et al. RNA Biology
- Leveraging Rational Protein Engineering to Improve mRNA Therapeutics
- (2018) Jeremiah D. Farelli et al. Nucleic Acid Therapeutics
- cmRNA/lipoplex encapsulation in PLGA microspheres enables transfection via calcium phosphate cement (CPC)/PLGA composites
- (2017) Maximilian Utzinger et al. JOURNAL OF CONTROLLED RELEASE
- Systemic delivery of factor IX messenger RNA for protein replacement therapy
- (2017) Suvasini Ramaswamy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
- (2017) Norbert Pardi et al. Nature Communications
- Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA
- (2017) Eva Schrom et al. Molecular Therapy-Nucleic Acids
- Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study
- (2016) Ygal Benhamou et al. AMERICAN JOURNAL OF HEMATOLOGY
- Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients
- (2016) Giulia Berti de Marinis et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
- (2016) Flora Peyvandi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models
- (2015) B. Pickens et al. BLOOD
- N 1 -methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice
- (2015) Oliwia Andries et al. JOURNAL OF CONTROLLED RELEASE
- Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
- (2015) Norbert Pardi et al. JOURNAL OF CONTROLLED RELEASE
- The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs
- (2014) M. Schaller et al. BLOOD
- Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura
- (2013) Marshall A. Mazepa et al. BRITISH JOURNAL OF HAEMATOLOGY
- Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura
- (2013) S. Ferrari et al. HAEMATOLOGICA
- Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura
- (2013) L. A. Lotta et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction
- (2013) Lior Zangi et al. NATURE BIOTECHNOLOGY
- A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13
- (2012) A. Schiviz et al. BLOOD
- Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura
- (2012) C. Jian et al. BLOOD
- Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice
- (2012) S. F. De Meyer et al. BLOOD
- Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura
- (2012) John Chapin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura
- (2011) Spero R. Cataland et al. AMERICAN JOURNAL OF HEMATOLOGY
- N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice
- (2011) Junmei Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies
- (2011) B. PLAIMAUER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- ADAMTS13 Bound to Endothelial Cells Exhibits Enhanced Cleavage of von Willebrand Factor
- (2009) Anthony N. Vomund et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Disintegrin-like and Metalloprotease (Reprolysin-type) with Thrombospondin Type 1 Motif (ADAMTS) Superfamily: Functions and Mechanisms
- (2009) Suneel S. Apte JOURNAL OF BIOLOGICAL CHEMISTRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started